179 related articles for article (PubMed ID: 6183037)
41. Effect of the converting enzyme inhibitor SQ-20881 on urinary excretion of prostaglandin E2 in the rat: influence of pretreatment with deoxycorticosterone.
Barr JG; Diz D; Kauker ML; Nasjletti A
J Pharmacol Exp Ther; 1980 Oct; 215(1):172-5. PubMed ID: 6161243
[TBL] [Abstract][Full Text] [Related]
42. Feedback analysis of the behavior of the renin-angiotensin system under inhibition of angiotensin-converting enzyme.
Wada T; Aoyagi T; Iinuma H; Ogawa K; Kojima F; Nagai M; Kuroda H; Obayashi A; Takeuchi T
Biotechnol Appl Biochem; 1988 Oct; 10(5):435-46. PubMed ID: 3058152
[TBL] [Abstract][Full Text] [Related]
43. Combined intrarenal renin-angiotensin blockade alters renal function and this is reversed by angiotensin II.
Siragy HM; Howell NL; Peach MJ; Carey RM
J Hypertens Suppl; 1989 Dec; 7(6):S174-5. PubMed ID: 2698923
[TBL] [Abstract][Full Text] [Related]
44. [Role of renin-angiotensin system and its blockaders in the pathogenesis of arterial hypertension].
Dimitrov T
Eksp Med Morfol; 1982; 21(1):1-5. PubMed ID: 6178577
[No Abstract] [Full Text] [Related]
45. Specificity of renal vasodilation with captopril: saralasin prevents the response in the DOCA-treated, salt-loaded rabbit.
Hollenberg NK; Passan DR
Life Sci; 1982 Jul; 31(4):329-34. PubMed ID: 6755124
[TBL] [Abstract][Full Text] [Related]
46. Combined intrarenal blockade of the renin-angiotensin system in the conscious dog.
Siragy HM; Howell NL; Peach MJ; Carey RM
Am J Physiol; 1990 Mar; 258(3 Pt 2):F522-9. PubMed ID: 2180318
[TBL] [Abstract][Full Text] [Related]
47. Effect of a converting enzyme inhibitor, angiotensin II, and saralasin on glomerular hemodynamics.
Heller J; Horácek V
Kidney Int Suppl; 1990 Nov; 30():S74-6. PubMed ID: 2259081
[No Abstract] [Full Text] [Related]
48. Comparison between saralsin and converting enzyme inhibitor in hypertensive disease.
Case DB; Wallace JM; Laragh JH
Kidney Int Suppl; 1979 Mar; (9):S107-114. PubMed ID: 225598
[No Abstract] [Full Text] [Related]
49. Renin-angiotensin influences on tubuloglomerular feedback activity in the rat.
Ploth DW; Roy RN
Kidney Int Suppl; 1982 Aug; 12():S114-21. PubMed ID: 6182337
[TBL] [Abstract][Full Text] [Related]
50. [Arguments in favor of postsynaptic antagonism by captopril (SQ 14,225) in the perfused kidney].
Casellas D; Chevillard C; Jover B; Dupont M; Mimran A
Arch Mal Coeur Vaiss; 1982 Jun; 75 Spec No():51-4. PubMed ID: 6180695
[TBL] [Abstract][Full Text] [Related]
51. Development of specific inhibitors of angiotensin I converting enzyme (kininase II).
Cushman DW; Cheung HS; Sabo EF; Rubin B; Ondetti MA
Fed Proc; 1979 Dec; 38(13):2778-82. PubMed ID: 228989
[No Abstract] [Full Text] [Related]
52. Failure of chronic administration of the angiotensin I-converting enzyme inhibitor, Teprotide (SQ 20881), to affect the ultrastructure of the adrenal cortex and the aldosterone secretion in the rat.
Weaver J; Nickerson PA; Molteni A; Solliday N; Albertson D
Lab Invest; 1981 Dec; 45(6):527-33. PubMed ID: 6172661
[TBL] [Abstract][Full Text] [Related]
53. Renal effects of angiotensin converting enzyme inhibitors in hypertension.
Bauer JH; Reams GP
Am J Med; 1986 Oct; 81(4C):19-27. PubMed ID: 3022581
[TBL] [Abstract][Full Text] [Related]
54. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor.
Morton JJ; Casals-Stenzel J; Lever AF; Millar JA; Riegger AJ; Tree M
Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):233S-241S. PubMed ID: 223615
[TBL] [Abstract][Full Text] [Related]
55. [Some advances in angiotensin converting enzyme inhibitors].
Jia L
Sheng Li Ke Xue Jin Zhan; 1985 Jul; 16(3):229-34. PubMed ID: 3003897
[No Abstract] [Full Text] [Related]
56. Effect of converting enzyme inhibition on the renal haemodynamic responses to noradrenaline infusion in the rat.
Arundell LA; Johns EJ
Br J Pharmacol; 1982 Mar; 75(3):553-8. PubMed ID: 6175369
[TBL] [Abstract][Full Text] [Related]
57. The effect of angiotensin I converting enzyme inhibitor (SQ 20881) on the release of prostaglandins by rabbit kidney, in vivo.
Johns EJ; Murdock R; Singer B
Br J Pharmacol; 1977 Aug; 60(4):573-81. PubMed ID: 198054
[TBL] [Abstract][Full Text] [Related]
58. Circulatory basis for the use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
Robertson JI
J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S2-8. PubMed ID: 2422488
[TBL] [Abstract][Full Text] [Related]
59. Glomerular actions of angiotensin II.
Ichikawa I; Brenner BM
Am J Med; 1984 May; 76(5B):43-9. PubMed ID: 6203406
[TBL] [Abstract][Full Text] [Related]
60. Effect of converting enzyme inhibitors on prostaglandin synthesis by isolated glomeruli and aortic strips from rats.
Galler M; Backenroth R; Folkert VW; Schlondorff D
J Pharmacol Exp Ther; 1982 Jan; 220(1):23-8. PubMed ID: 6171637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
